{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:20:39Z","timestamp":1790371239389,"version":"4.1.0"},"reference-count":189,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptors and their biology has promoted the development of synthetic ligands. The possibility of targeting these receptors to treat NAFLD is promising, as several compounds including Cilofexor, thiazolidinediones, and Saroglitazar are currently undergoing clinical trials. This review focuses on the latest development of the pharmacology of these metabolic nuclear receptors and how they may be utilized to treat NAFLD and subsequent comorbidities.<\/jats:p>","DOI":"10.3390\/metabo12030238","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T22:29:43Z","timestamp":1647210583000},"page":"238","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH"],"prefix":"10.3390","volume":"12","author":[{"given":"Ryan D.","family":"Welch","sequence":"first","affiliation":[{"name":"Biology and Chemistry Department, Blackburn College, Carlinville, IL 62626, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Billon","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna","family":"Losby","sequence":"additional","affiliation":[{"name":"Biochemistry, Biophysics and Structural Biology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Bedia-Diaz","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanying","family":"Fang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Avdagic","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-7976","authenticated-orcid":false,"given":"Bahaa","family":"Elgendy","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University in St. Louis, St. Louis, MO 63110, USA"},{"name":"Department of Anesthesiology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Burris","sequence":"additional","affiliation":[{"name":"UF Genetics Institute, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-2518","authenticated-orcid":false,"given":"Kristine","family":"Griffett","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2011.08.041","article-title":"NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages","volume":"220","author":"Bieghs","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2012.11.014","article-title":"Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins","volume":"58","author":"Walenbergh","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Oligschlaeger, Y., and Shiri-Sverdlov, R. (2020). NAFLD Preclinical Models: More than a Handful, Less of a Concern?. Biomedicines, 8.","DOI":"10.3390\/biomedicines8020028"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, J., Chanda, D., van Gorp, P.J., Jeurissen, M.L., Houben, T., Walenbergh, S.M., Debets, J., Oligschlaeger, Y., Gijbels, M.J., and Neumann, D. (2016). Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163843"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"14956","DOI":"10.1038\/s41598-019-51525-x","article-title":"Hematopoietic Npc1 mutation shifts gut microbiota composition in Ldlr\u2212\/\u2212 mice on a high-fat, high-cholesterol diet","volume":"9","author":"Houben","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000282080","article-title":"Epidemiology of Non-Alcoholic Fatty Liver Disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1665-2681(19)32110-6","article-title":"Fatty liver: How frequent is it and why?","volume":"3","author":"Bedogni","year":"2004","journal-title":"Ann. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000323886","article-title":"ASH and NASH","volume":"29","author":"Scaglioni","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hep.23901","article-title":"Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease","volume":"53","author":"Targher","year":"2010","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-5491.2006.01975.x","article-title":"Obesity and Diabetes","volume":"23","author":"Targher","year":"2006","journal-title":"Diabet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2006.06.004","article-title":"Non-alcoholic fatty liver disease as a determinant of cardiovascular disease","volume":"190","author":"Targher","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20070311","article-title":"Is liver fat detrimental to vessels?: Intersections in the pathogenesis of NAFLD and atherosclerosis","volume":"115","author":"Loria","year":"2008","journal-title":"Clin. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"A758","article-title":"The role of endotoxin, Kupffer cell and its related cytokines in the pathogenesis of nonalcoholic steatohepatitis in rats","volume":"124","author":"Jiangao","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/j.1572-0241.2003.07736.x","article-title":"Nonalcoholic steatohepatitis: Role of leptin in pathogenesis and benefits of metformin in treatment","volume":"98","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.hepres.2005.09.019","article-title":"The role of oxidative stress in NASH and fatty liver model","volume":"33","author":"Sakaida","year":"2005","journal-title":"Hepatol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.freeradbiomed.2012.08.336","article-title":"Increase of oxidative stress in NASH by increased levels of citrate","volume":"53","author":"Haenen","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.26749","article-title":"Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH","volume":"59","author":"Sutti","year":"2014","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3164\/jcbn.38.127","article-title":"Pathophysiology of NASH: Insulin Resistance, Free Fatty Acids and Oxidative Stress","volume":"38","author":"Shiota","year":"2006","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jhep.2005.09.008","article-title":"Nrf1 gene expression in the liver: A single gene linking oxidative stress to NAFLD, NASH and hepatic tumours","volume":"43","author":"Parola","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0168-8278(17)30338-0","article-title":"Direct activation of Nlrp3 inflammasome in hepatic stellate cells leads to upregulation of fibrotic markers","volume":"66","author":"Inzaugarat","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_27","first-page":"E2","article-title":"Inability to form NLRP3 inflammasome complex leads to decreased inflammation and prevents fibrosis formation in mice after chronic bile duct ligation","volume":"56","author":"Frissen","year":"2017","journal-title":"Z. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut\u2013Liver Axis in Alcoholic Liver Disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease","volume":"140","author":"Hotamisligil","year":"2010","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nm0211-164","article-title":"Linking the inflammasome to obesity-related disease","volume":"17","author":"Horng","year":"2011","journal-title":"Nat. Med."},{"key":"ref_31","first-page":"1069","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"Klin. Wochenschr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2013","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4172\/2168-9431.1000140","article-title":"Role of ER Stress in Inflammasome Activation and Non-Alcoholic Fatty Liver Disease Progression","volume":"5","author":"Lebeaupin","year":"2016","journal-title":"Single Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/pr.112.006833","article-title":"Nuclear Receptors and Their Selective Pharmacologic Modulators","volume":"65","author":"Burris","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0092-8674(88)90255-3","article-title":"Transcriptional inhibition by a glucocorticoid receptor-\u03b2-galactosidase fusion protein","volume":"55","author":"Oro","year":"1988","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: A master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/en.2004-1595","article-title":"Farnesoid X Receptor: A New Player in Glucose Metabolism?","volume":"146","author":"Cariou","year":"2005","journal-title":"Endocrinology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.livres.2020.03.001","article-title":"Nuclear receptors and non-alcoholic fatty liver disease: An update","volume":"4","author":"Yang","year":"2020","journal-title":"Liver Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40495-017-0085-2","article-title":"Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis","volume":"3","author":"Armstrong","year":"2017","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Han, C. (2018). Update on FXR Biology: Promising Therapeutic Target?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072069"},{"key":"ref_43","first-page":"28","article-title":"Trials of obeticholic acid for non-alcoholic steatohepatitis\u2014Authors\u2019 reply","volume":"386","author":"Tonascia","year":"2015","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_45","first-page":"S151","article-title":"Pharmacokinetics of selonsertib, GS-9674, and\/or GS-0976 in combination in healthy subjects","volume":"66","author":"Nelson","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S0618-8278(19)31582-8","article-title":"SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis","volume":"70","author":"Lawitz","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S1166","DOI":"10.1016\/S0016-5085(18)33863-0","article-title":"Su1522\u2014Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH","volume":"154","author":"Lawitz","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hep4.1342","article-title":"Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment","volume":"3","author":"Alkhouri","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"172661","DOI":"10.1016\/j.ejphar.2019.172661","article-title":"Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis","volume":"863","author":"Venetsanaki","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000369152","article-title":"Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease","volume":"129","author":"Lin","year":"2014","journal-title":"Nephron"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1021\/acs.jmedchem.5b01161","article-title":"Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia","volume":"58","author":"Genin","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.febslet.2007.11.040","article-title":"PPAR\u03b4 as a therapeutic target in metabolic disease","volume":"582","author":"Reilly","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13919","DOI":"10.1073\/pnas.241410198","article-title":"Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors","volume":"98","author":"Xu","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"37731","DOI":"10.1074\/jbc.R100034200","article-title":"PPAR\u03b3: A Nuclear Regulator of Metabolism, Differentiation, and Cell Growth","volume":"276","author":"Rosen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wang, Y., Nakajima, T., Gonzalez, F.J., and Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062061"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Liu, Y., Colby, J., Zuo, X., Jaoude, J., Wei, D., and Shureiqi, I. (2018). The Role of PPAR-\u03b4 in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113339"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1301\/nr.2003.nov.387-390","article-title":"The Function of the Nuclear Receptor Peroxisome Proliferator\u2013activated Receptor Delta in Energy Homeostasis","volume":"61","author":"Wolf","year":"2003","journal-title":"Nutr. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications\u2014A review","volume":"13","year":"2014","journal-title":"Nutr. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator\u2212Activated Receptor\u2212\u03b1 and \u2212\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic Landscape for NAFLD in 2020","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00210-019-01703-5","article-title":"The dual PPAR-\u03b1\/\u03b3 agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin","volume":"392","author":"Makled","year":"2019","journal-title":"Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2017","journal-title":"Liver Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) \u03b1\/\u03b3\/\u03b4 Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","article-title":"Pemafibrate: First Global Approval","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/383728a0","article-title":"An oxysterol signalling pathway mediated by the nuclear receptor LXR\u03b1","volume":"383","author":"Janowski","year":"1996","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0092-8674(00)81432-4","article-title":"Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXR\u03b1","volume":"93","author":"Peet","year":"1998","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0959-437X(98)80013-0","article-title":"The LXRs: A new class of oxysterol receptors","volume":"8","author":"Peet","year":"1998","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1073\/pnas.96.1.266","article-title":"Structural requirements of ligands for the oxysterol liver X receptors LXR and LXR","volume":"96","author":"Janowski","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2015.06.042","article-title":"Liver X receptors at the intersection of lipid metabolism and atherogenesis","volume":"242","author":"Lee","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: Opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/me.2003-0061","article-title":"Liver X Receptor Signaling Pathways in Cardiovascular Disease","volume":"17","author":"Tontonoz","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"38378","DOI":"10.1074\/jbc.M105805200","article-title":"27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells","volume":"276","author":"Fu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1126\/science.174194","article-title":"Receptor-mediated control of cholesterol metabolism","volume":"191","author":"Brown","year":"1976","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1210\/me.2008-0398","article-title":"Minireview: Liver X Receptor \u03b2: Emerging Roles in Physiology and Diseases","volume":"23","author":"Gabbi","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.25812","article-title":"Bile acids in nonalcoholic steatohepatitis: Inserting nuclear receptors into the circle","volume":"56","author":"Gabbi","year":"2012","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1093-3263(03)00159-1","article-title":"Molecular determinants of LXR\u03b1 agonism","volume":"22","author":"Wang","year":"2003","journal-title":"J. Mol. Graph. Model."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/jpet.103.052852","article-title":"A Natural Product Ligand of the Oxysterol Receptor, Liver X Receptor","volume":"307","author":"Bramlett","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta","volume":"14","author":"Repa","year":"2000","journal-title":"Genes Dev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1751-2980.2011.00554.x","article-title":"Liver X receptors bridge hepatic lipid metabolism and inflammation","volume":"13","author":"Liu","year":"2012","journal-title":"J. Dig. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm820","article-title":"Reciprocal regulation of inflammation and lipid metabolism by liver X receptors","volume":"9","author":"Joseph","year":"2003","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.1074\/jbc.M213071200","article-title":"Liver X Receptor-dependent Repression of Matrix Metalloproteinase-9 Expression in Macrophages","volume":"278","author":"Castrillo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1194\/jlr.M010686","article-title":"Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: Identification of ARL7 as a direct target","volume":"52","author":"Hong","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1073\/pnas.98.2.507","article-title":"LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes","volume":"98","author":"Laffitte","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.ATV.0000152727.69018.61","article-title":"Lesion Macrophages Are a Key Target for the Antiatherogenic Effects of LXR Agonists","volume":"25","author":"Bradley","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.109.191197","article-title":"Liver X Receptor Signaling Pathways and Atherosclerosis","volume":"30","author":"Calkin","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","article-title":"Synthetic LXR ligand inhibits the development of atherosclerosis in mice","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03578-0","article-title":"T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice","volume":"536","author":"Terasaka","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2018.73155","article-title":"The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases","volume":"4","author":"Piekarska","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7869\/tg.2012.101","article-title":"Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease","volume":"34","author":"Guleria","year":"2013","journal-title":"Trop. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.atherosclerosis.2018.06.587","article-title":"Pre-clinical vascular damage in metabolic syndrome: Correlation between nafld and carotid disease","volume":"275","author":"Veca","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/j.atherosclerosis.2017.06.840","article-title":"Risk factor for NAFLD and CHD\u2014Similarity and differences","volume":"263","author":"Pojskic","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2018.01.023","article-title":"New insights into NAFLD and subclinical coronary atherosclerosis","volume":"68","author":"VanWagner","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.febslet.2007.03.047","article-title":"T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR","volume":"581","author":"Mitro","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5352\/JLS.2011.21.4.481","article-title":"T0901317 as an Inhibitor of Transcriptional Activation of Constitutive Androstane Receptor (CAR)","volume":"21","author":"Kim","year":"2011","journal-title":"J. Life Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2007.03.116","article-title":"The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells","volume":"357","author":"Chuu","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2131\/jts.38.309","article-title":"T0901317, a potent LXR agonist, is an inverse agonist of CAR","volume":"38","author":"Kanno","year":"2013","journal-title":"J. Toxicol. Sci."},{"key":"ref_102","first-page":"450","article-title":"GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats","volume":"151","author":"Leik","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1124\/mol.107.037358","article-title":"Physiological Differences between Human and Rat Primary Hepatocytes in Response to Liver X Receptor Activation by 3-[3-[N-(2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy]phenylacetic Acid Hydrochloride (GW3965)","volume":"72","author":"Kotokorpi","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1567-5688(10)70827-8","article-title":"MS326 LXR activation with T0901317 and GW3965 in mice: Differential effects on liver and intestine, but no negative impact on bone","volume":"11","author":"Prawitt","year":"2010","journal-title":"Atheroscler. Suppl."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00041433-200412000-00012","article-title":"Lipid metabolism: Is liver X receptor (LXR) a regulator of adipocyte differentiation? Consequences of stearoyl-CoA desaturase activation by LXR","volume":"15","author":"Narce","year":"2004","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2337\/db09-1542","article-title":"Acute Inhibition of Fatty Acid Import Inhibits GLUT4 Transcription in Adipose Tissue, but Not Skeletal or Cardiac Muscle Tissue, Partly Through Liver X Receptor (LXR) Signaling","volume":"59","author":"Griesel","year":"2010","journal-title":"Diabetes"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.addr.2010.07.006","article-title":"Functional crosstalk of CAR\u2013LXR and ROR\u2013LXR in drug metabolism and lipid metabolism","volume":"62","author":"Xiao","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants","volume":"49","author":"Katz","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cb300541g","article-title":"A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis","volume":"8","author":"Griffett","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2015.05.007","article-title":"Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis","volume":"28","author":"Flaveny","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/cb3002649","article-title":"Identification of a Selective ROR\u03b3 Ligand That Suppresses TH17 Cells and Stimulates T Regulatory Cells","volume":"7","author":"Solt","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1101\/gad.8.5.538","article-title":"Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors","volume":"8","author":"Giguere","year":"1994","journal-title":"Genes Dev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1126\/science.288.5475.2369","article-title":"Requirement for RORgamma in Thymocyte Survival and Lymphoid Organ Development","volume":"288","author":"Sun","year":"2000","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molmet.2016.07.001","article-title":"Inhibition of ROR\u03b1\/\u03b3 suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation","volume":"5","author":"Billon","year":"2016","journal-title":"Mol. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0378-1119(98)00348-5","article-title":"A novel isoform of the orphan nuclear receptor ROR\u03b2 is specifically expressed in pineal gland and retina","volume":"216","author":"Gawlas","year":"1998","journal-title":"Gene"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0378-1119(96)00504-5","article-title":"Cloning of a cDNA encoding the murine orphan receptor RZR\/ROR\u03b3 and characterization of its response element","volume":"181","author":"Medvedev","year":"1996","journal-title":"Gene"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1074\/jbc.M109.080614","article-title":"Modulation of Retinoic Acid Receptor-related Orphan Receptor \u03b1 and \u03b3 Activity by 7-Oxygenated Sterol Ligands","volume":"285","author":"Wang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_119","first-page":"917","article-title":"A second class of nuclear receptors for oxysterols: Regulation of ROR\u03b1 and ROR\u03b3 activity by 24S-hydroxycholesterol (cerebrosterol)","volume":"1801","author":"Wang","year":"2010","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/cb1002762","article-title":"Identification of SR3335 (ML-176): A Synthetic ROR\u03b1 Selective Inverse Agonist","volume":"6","author":"Kumar","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/cb100223d","article-title":"Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors ROR\u03b1 and ROR\u03b3","volume":"5","author":"Wang","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s12272-012-0809-0","article-title":"N-methylthioureas as new agonists of retinoic acid receptor-related orphan receptor","volume":"35","author":"Park","year":"2012","journal-title":"Arch. Pharmacal Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature09978","article-title":"Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR\u03b3t activity","volume":"472","author":"Huh","year":"2011","journal-title":"Nature"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1152\/physiolgenomics.00206.2010","article-title":"Transcriptional profiling reveals a role for ROR\u03b1 in regulating gene expression in obesity-associated inflammation and hepatic steatosis","volume":"43","author":"Kang","year":"2011","journal-title":"Physiol. Genom."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00125-011-2046-3","article-title":"Homozygous staggerer (sg\/sg) mice display improved insulin sensitivity and enhanced glucose uptake in skeletal muscle","volume":"54","author":"Lau","year":"2011","journal-title":"Diabetologia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fendo.2017.00141","article-title":"Metabolic Characterization of a Novel ROR\u03b1 Knockout Mouse Model without Ataxia","volume":"8","author":"Billon","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/s41598-017-16077-y","article-title":"Liver-specific deletion of ROR\u03b1 aggravates diet-induced nonalcoholic steatohepatitis by inducing mitochondrial dysfunction","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.molmet.2019.02.010","article-title":"Liver-specific ROR\u03b1 deletion does not affect the metabolic susceptibility to western style diet feeding","volume":"23","author":"Molinaro","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.celrep.2017.06.017","article-title":"ROR\u03b1 Induces KLF4-Mediated M2 Polarization in the Liver Macrophages that Protect against Nonalcoholic Steatohepatitis","volume":"20","author":"Han","year":"2017","journal-title":"Cell Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.25529","article-title":"Retinoic acid receptor-related orphan receptor \u03b1-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis","volume":"55","author":"Kim","year":"2012","journal-title":"Hepatology"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Starmann, J., F\u00e4lth, M., Spindelb\u00f6ck, W., Lanz, K.L., Lackner, C., Zatloukal, K., Trauner, M., and S\u00fcltmann, H. (2012). Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046584"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/hep.27695","article-title":"Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids","volume":"61","author":"Arendt","year":"2015","journal-title":"Hepatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1053\/j.gastro.2020.05.056","article-title":"Agonist of RORA Attenuates Non-Alcoholic Fatty Liver Progression in Mice via Upregulation of microRNA 122","volume":"159","author":"Chai","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"S702","DOI":"10.1016\/S0016-5085(11)62918-1","article-title":"Interleukin-17 Integrates Hepatic Steatosis and Inflammation in Nonalcoholic Fatty Liver Disease","volume":"140","author":"Ma","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.dld.2018.01.033","article-title":"Modulation of the NLRP3 inflammasome pathway mediates the anti-inflammatory action of indoleamine dioxygenase in experimental NASH","volume":"50","author":"Vivoli","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13071-018-3223-8","article-title":"NLRP3 inflammasome activation from Kupffer cells is involved in liver fibrosis of Schistosoma japonicum-infected mice via NF-\u03baB","volume":"12","author":"Zhang","year":"2019","journal-title":"Parasites Vectors"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1074\/jbc.AC118.002127","article-title":"ROR\u03b3 regulates the NLRP3 inflammasome","volume":"294","author":"Billon","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1073\/pnas.1106750109","article-title":"The nuclear receptor REV-ERB mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines","volume":"109","author":"Gibbs","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1152\/japplphysiol.00570.2009","article-title":"Rev-erb-\u03b1: An integrator of circadian rhythms and metabolism","volume":"107","author":"Duez","year":"2009","journal-title":"J. Appl. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1101\/gad.186858.112","article-title":"Rev-erb and Rev-erb coordinately protect the circadian clock and normal metabolic function","volume":"26","author":"Bugge","year":"2012","journal-title":"Genes Dev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41574-018-0150-x","article-title":"Circadian rhythms and exercise\u2014Re-setting the clock in metabolic disease","volume":"15","author":"Gabriel","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S0168-8278(12)60391-2","article-title":"378 functional role of rev-erb in modulation of hepatic stellate cell transdifferentiation","volume":"56","author":"Li","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature11048","article-title":"Regulation of circadian behaviour and metabolism by REV-ERB-\u03b1 and REV-ERB-\u03b2","volume":"485","author":"Cho","year":"2012","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/nsmb1344","article-title":"Identification of heme as the ligand for the orphan nuclear receptors REV-ERB\u03b1 and REV-ERB\u03b2","volume":"14","author":"Raghuram","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/me.2007-0519","article-title":"Nuclear Hormone Receptors for Heme: REV-ERB\u03b1 and REV-ERB\u03b2 Are Ligand-Regulated Components of the Mammalian Clock","volume":"22","author":"Burris","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1021\/cb100141y","article-title":"GSK4112, a Small Molecule Chemical Probe for the Cell Biology of the Nuclear Heme Receptor Rev-erb\u03b1","volume":"5","author":"Grant","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/cb1002575","article-title":"Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB","volume":"6","author":"Kojetin","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature11030","article-title":"Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists","volume":"485","author":"Solt","year":"2012","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1194\/jlr.M200386-JLR200","article-title":"Identification of Rev-erb\u03b1 as a physiological repressor of apoC-III gene transcription","volume":"43","author":"Duez","year":"2002","journal-title":"J. Lipid Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41569-020-0351-6","article-title":"Dual apoC-II mimetic and apoC-III antagonist for hypertriglyceridaemia","volume":"17","author":"Huynh","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1194\/jlr.M600230-JLR200","article-title":"Elovl3, a model gene to dissect homeostatic links between the circadian clock and nutritional status","volume":"47","author":"Anzulovich","year":"2006","journal-title":"J. Lipid Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Le Martelot, G., Claudel, T., Gatfield, D., Schaad, O., Kornmann, B., Sasso, G.L., Moschetta, A., and Schibler, U. (2009). REV-ERB\u03b1 Participates in Circadian SREBP Signaling and Bile Acid Homeostasis. PLoS Biol., 7.","DOI":"10.1371\/journal.pbio.1000181"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1097\/00042737-200601000-00149","article-title":"Role of the nuclear orphan receptor Rev-erb\u00e1; in the regulation of bile acid synthesis","volume":"18","author":"Claudel","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2008.05.035","article-title":"Regulation of Bile Acid Synthesis by the Nuclear Receptor Rev-erb\u03b1","volume":"135","author":"Duez","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2003.11.006","article-title":"Regulation of bile acid synthesis: Pathways, nuclear receptors, and mechanisms","volume":"40","author":"Chiang","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2015.03.070","article-title":"Suppression of atherosclerosis by synthetic REV-ERB agonist","volume":"460","author":"Sitaula","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2017.02.006","article-title":"Rev-erb regulation of cholesterologenesis","volume":"131","author":"Sitaula","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Griffett, K., Bedia-Diaz, G., Elgendy, B., and Burris, T.P. (2020). REV-ERB agonism improves liver pathology in a mouse model of NASH. PLoS ONE, 15.","DOI":"10.1101\/2020.06.29.177378"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1172\/JCI96138","article-title":"REVERBa couples the circadian clock to hepatic glucocorticoid action","volume":"128","author":"Caratti","year":"2018","journal-title":"J. Clin. Am. Soc. Clin. Investig."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: Molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.12.019","article-title":"Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice","volume":"154","author":"Pourcet","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1038\/s41467-018-06568-5","article-title":"REV-ERB\u03b1 integrates colon clock with experimental colitis through regulation of NF-\u03baB\/NLRP3 axis","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s42003-019-0595-z","article-title":"SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome","volume":"2","author":"Reitz","year":"2019","journal-title":"Commun. Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41401-018-0064-0","article-title":"Pharmacological activation of REV-ERB\u03b1 represses LPS-induced microglial activation through the NF-\u03baB pathway","volume":"40","author":"Guo","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1073\/pnas.1812405116","article-title":"Circadian clock protein Rev-erb\u03b1 regulates neuroinflammation","volume":"116","author":"Griffin","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/331091a0","article-title":"Identification of a new class of steroid hormone receptors","volume":"331","author":"Yang","year":"1988","journal-title":"Nature"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/er.2008-0017","article-title":"Transcriptional Control of Energy Homeostasis by the Estrogen-Related Receptors","volume":"29","year":"2008","journal-title":"Endocr. Rev."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(98)00619-2","article-title":"Identification of two hERR2-related novel nuclear receptors utilizing bioinformatics and inverse PCR","volume":"228","author":"Chen","year":"1999","journal-title":"Gene"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1128\/MCB.17.9.5400","article-title":"The orphan nuclear receptor estrogen-related receptor alpha is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene","volume":"17","author":"Sladek","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_173","first-page":"51","article-title":"The multiple universes of estrogen-related receptor \u03b1 and \u03b3 in metabolic control and related diseases","volume":"36","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ceb.2014.11.002","article-title":"PPARs and ERRs: Molecular mediators of mitochondrial metabolism","volume":"33","author":"Fan","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cmet.2011.01.019","article-title":"Exercise and PGC-1\u03b1-Independent Synchronization of Type I Muscle Metabolism and Vasculature by ERR\u03b3","volume":"13","author":"Narkar","year":"2011","journal-title":"Cell Metab."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2007.06.007","article-title":"ERR\u03b3 Directs and Maintains the Transition to Oxidative Metabolism in the Postnatal Heart","volume":"6","author":"Alaynick","year":"2007","journal-title":"Cell Metab."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1021\/jm049334f","article-title":"Identification of a Selective Inverse Agonist for the Orphan Nuclear Receptor Estrogen-Related Receptor \u03b1","volume":"47","author":"Busch","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/jm101063h","article-title":"Identification of Diaryl Ether-Based Ligands for Estrogen-Related Receptor \u03b1 as Potential Antidiabetic Agents","volume":"54","author":"Patch","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ejmech.2017.07.015","article-title":"Indazole-based ligands for estrogen-related receptor \u03b1 as potential anti-diabetic agents","volume":"138","author":"Patch","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"22619","DOI":"10.1074\/jbc.M110.125401","article-title":"Estrogen-related Receptor \u03b3 Is a Key Regulator of Muscle Mitochondrial Activity and Oxidative Capacity","volume":"285","author":"Rangwala","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"21628","DOI":"10.1074\/jbc.M111.315168","article-title":"Orphan Nuclear Receptor Estrogen-Related Receptor \u03b3 (ERR\u03b3) Is Key Regulator of Hepatic Gluconeogenesis","volume":"287","author":"Kim","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/42022","article-title":"Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-\u03b2","volume":"388","author":"Luo","year":"1997","journal-title":"Nature"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2006.10.012","article-title":"Receptor-Selective Coactivators as Tools to Define the Biology of Specific Receptor-Coactivator Pairs","volume":"24","author":"Gaillard","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1101\/gad.1871610","article-title":"The homeobox protein Prox1 is a negative modulator of ERR\/PGC-1 bioenergetic functions","volume":"24","author":"Dufour","year":"2010","journal-title":"Genes Dev."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cmet.2013.03.003","article-title":"Molecular and Genetic Crosstalks between mTOR and ERR\u03b1 Are Key Determinants of Rapamycin-Induced Nonalcoholic Fatty Liver","volume":"17","author":"Chaveroux","year":"2013","journal-title":"Cell Metab."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1074\/jbc.M509276200","article-title":"Estrogen-related Receptor \u03b1 Is a Repressor of Phosphoenolpyruvate Carboxykinase Gene Transcription","volume":"281","author":"Herzog","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.1128\/MCB.23.22.7947-7956.2003","article-title":"Reduced Fat Mass in Mice Lacking Orphan Nuclear Receptor Estrogen-Related Receptor \u03b1","volume":"23","author":"Luo","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"23664","DOI":"10.1038\/srep23664","article-title":"NADPH oxidase is implicated in the pathogenesis of oxidative phosphorylation dysfunction in mice fed a high-fat diet","volume":"6","author":"Grau","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/en.2018-00115","article-title":"Divergent Role of Estrogen-Related Receptor \u03b1 in Lipid- and Fasting-Induced Hepatic Steatosis in Mice","volume":"159","author":"Dufour","year":"2018","journal-title":"Endocrinology"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/12\/3\/238\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:13Z","timestamp":1760135713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/12\/3\/238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":189,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["metabo12030238"],"URL":"https:\/\/doi.org\/10.3390\/metabo12030238","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}